Carine Cohen, PhD

Pharmacoepidemiologist

Carine has 20+ years of experience in big pharma’s. Here, she speaks as a patient, with early Breast Cancer. After an initial response, her prognosis got compromised by disease progression in her lymph node. Indeed, Ribolaris trial aims to replicate at large-scale this acquired resistance phenomenon (escape in the Ki67) triggered by neoadjuvant Ribociclib, impacting 67-73% of the patients in FELINE (Griffiths et al.) and Coralleen trials. Since August 2023, she is struggling with no success to engage with Novartis, asking for their 5-year overall survival data from FELINE trial, hoping to inform and rescue the other victims. In her relentless quest for rescue treatments, she came across another Novartis saga, impairing the safety and ethics of Everolimus, another cancer drug.